---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-010537"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:44:53.089048+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma Q1 net loss $2.3M, cash $6.9M; CDI-988 shows broad norovirus activity, human challenge planned

## Summary
- Net loss for Q1 2025 was $2.3M ($0.23/share) vs $4.0M ($0.39/share) in Q1 2024.
- R&D expenses decreased to $1.4M from $3.0M; G&A down to $1.0M from $1.2M.
- Unrestricted cash $6.9M at March 31, 2025 vs $9.9M at Dec 31, 2024; working capital $6.9M.
- CDI-988 showed superior broad-spectrum antiviral activity against norovirus GII.17 strains; expects to report topline Phase 1 high-dose results in Q2 2025.
- Plan to initiate a U.S. human challenge study for CDI-988 as norovirus treatment and prophylaxis in coming months.

## SEC filing metadata
- accession: 0001641172-25-010537
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000164117225010537/0001641172-25-010537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000164117225010537/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-010537
- JSON: https://secwatch.observer/filing/0001641172-25-010537.json
- Plain text: https://secwatch.observer/filing/0001641172-25-010537.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.